-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang No.4 Pharmaceutical’s moxifloxacin hydrochloride sodium chloride injection has passed the consistency evaluation.
Category:
Time：2020-12-03
Recently, Shijiazhuang No.4 Pharmaceutical’s moxifloxacin hydrochloride sodium chloride injection has been approved by the National Medical Products Administration to pass the evaluation of bioequivalence and therapeutic equivalence for generic drugs.
Moxifloxacin Hydrochloride Sodium Injection belongs to Category 6 of the original chemical drugs and has been included in the National Essential Medicines List. Moxifloxacin is a fourth-generation quinolone antibacterial agent and a new-generation antibiotic with a broad-spectrum antimicrobial profile. It is primarily used to treat various bacterial infections, including pneumonia, tuberculosis, endocarditis, conjunctivitis (pink eye), and respiratory tract infections. Earlier this year, Shijiazhuang Fourth Pharmaceutical Company urgently provided emergency support and donations—including Moxifloxacin Hydrochloride Sodium Injection and Abidol Hydrochloride Capsules—of antibacterial and antiviral medications to Wuhan, Hubei Province, and the Shennongjia Forestry District, playing a positive role in clinical treatment and rescue efforts.
It is reported that, as of now, Shijiazhuang No.4 Pharmaceutical has had a total of nine specifications across seven product categories—fluconazole tablets (50mg, 150mg), prucalopride succinate tablets (1mg, 2mg), cefdinir capsules (0.1mg), rosuvastatin calcium tablets (10mg), doxofylline injection, ropivacaine hydrochloride injection, and moxifloxacin hydrochloride sodium injection—pass the National Generic Drug Quality and Efficacy Consistency Evaluation or be deemed to have passed such evaluation. The person in charge stated that the company will continue to accelerate the development of generic drugs and advance research on generic drug consistency evaluation, striving to create new opportunities and room for maneuver to build a new product structure and adapt to emerging changes in market demand.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code